TERN Quote, Financials, Valuation and Earnings

ADMA Biologics, Inc. has a net margin of -- compared to Terns Pharmaceuticals, Inc.'s net margin of 27.14%. Terns Pharmaceuticals, Inc.'s return on equity of -29.05% beat ADMA Biologics, Inc.'s return on equity of 58.71%.

Terns Pharmaceuticals, Inc. has a consensus price target of $53.56, signalling upside risk potential of 26.37%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 31.69%. Given that ADMA Biologics, Inc. has higher upside potential than Terns Pharmaceuticals, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Terns Pharmaceuticals, Inc..

Terns Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.

Terns Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.

Terns Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Terns Pharmaceuticals, Inc.'s net income of -$24.6M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Terns Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 22.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals, Inc. is -- versus 9.83x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Altimmune, Inc. has a net margin of -- compared to Terns Pharmaceuticals, Inc.'s net margin of -380280%. Terns Pharmaceuticals, Inc.'s return on equity of -29.05% beat Altimmune, Inc.'s return on equity of -56.24%.

Terns Pharmaceuticals, Inc. has a consensus price target of $53.56, signalling upside risk potential of 26.37%. On the other hand Altimmune, Inc. has an analysts' consensus of $17.75 which suggests that it could grow by 343.75%. Given that Altimmune, Inc. has higher upside potential than Terns Pharmaceuticals, Inc., analysts believe Altimmune, Inc. is more attractive than Terns Pharmaceuticals, Inc..

Terns Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Altimmune, Inc. has a beta of -0.029, suggesting its less volatile than the S&P 500 by 102.89%.

Terns Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Altimmune, Inc. pays out -- of its earnings as a dividend.

Terns Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Altimmune, Inc. quarterly revenues of $5K. Terns Pharmaceuticals, Inc.'s net income of -$24.6M is lower than Altimmune, Inc.'s net income of -$19M. Notably, Terns Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Altimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals, Inc. is -- versus 15,885.21x for Altimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals, Inc. has a net margin of -- compared to Terns Pharmaceuticals, Inc.'s net margin of -103.13%. Terns Pharmaceuticals, Inc.'s return on equity of -29.05% beat Rhythm Pharmaceuticals, Inc.'s return on equity of -509.34%.

Terns Pharmaceuticals, Inc. has a consensus price target of $53.56, signalling upside risk potential of 26.37%. On the other hand Rhythm Pharmaceuticals, Inc. has an analysts' consensus of $139.00 which suggests that it could grow by 23.81%. Given that Terns Pharmaceuticals, Inc. has higher upside potential than Rhythm Pharmaceuticals, Inc., analysts believe Terns Pharmaceuticals, Inc. is more attractive than Rhythm Pharmaceuticals, Inc..

Terns Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals, Inc. has a beta of 1.963, suggesting its more volatile than the S&P 500 by 96.257%.

Terns Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Rhythm Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Terns Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Rhythm Pharmaceuticals, Inc. quarterly revenues of $51.3M. Terns Pharmaceuticals, Inc.'s net income of -$24.6M is higher than Rhythm Pharmaceuticals, Inc.'s net income of -$52.9M. Notably, Terns Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Rhythm Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals, Inc. is -- versus 40.99x for Rhythm Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of -- compared to Terns Pharmaceuticals, Inc.'s net margin of --. Terns Pharmaceuticals, Inc.'s return on equity of -29.05% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.

Terns Pharmaceuticals, Inc. has a consensus price target of $53.56, signalling upside risk potential of 26.37%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 150.04%. Given that Viking Therapeutics, Inc. has higher upside potential than Terns Pharmaceuticals, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Terns Pharmaceuticals, Inc..

Terns Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.

Terns Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.

Terns Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Viking Therapeutics, Inc. quarterly revenues of --. Terns Pharmaceuticals, Inc.'s net income of -$24.6M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Terns Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals, Inc. is -- versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.